NO20026286D0 - Nye peptider - Google Patents

Nye peptider

Info

Publication number
NO20026286D0
NO20026286D0 NO20026286A NO20026286A NO20026286D0 NO 20026286 D0 NO20026286 D0 NO 20026286D0 NO 20026286 A NO20026286 A NO 20026286A NO 20026286 A NO20026286 A NO 20026286A NO 20026286 D0 NO20026286 D0 NO 20026286D0
Authority
NO
Norway
Prior art keywords
new peptides
growth factor
vascular endothelial
endothelial growth
receptor
Prior art date
Application number
NO20026286A
Other languages
English (en)
Norwegian (no)
Inventor
Mari Ann Kulseth
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Health As filed Critical Amersham Health As
Priority to NO20026286A priority Critical patent/NO20026286D0/no
Publication of NO20026286D0 publication Critical patent/NO20026286D0/no
Priority to PCT/NO2003/000444 priority patent/WO2004058802A1/en
Priority to DE60319135T priority patent/DE60319135D1/de
Priority to JP2004563063A priority patent/JP2006523608A/ja
Priority to AT03781116T priority patent/ATE386050T1/de
Priority to EP03781116A priority patent/EP1578785B1/en
Priority to AU2003288810A priority patent/AU2003288810A1/en
Priority to US10/540,431 priority patent/US20060089307A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
NO20026286A 2002-12-30 2002-12-30 Nye peptider NO20026286D0 (no)

Priority Applications (8)

Application Number Priority Date Filing Date Title
NO20026286A NO20026286D0 (no) 2002-12-30 2002-12-30 Nye peptider
PCT/NO2003/000444 WO2004058802A1 (en) 2002-12-30 2003-12-29 Peptides that bind to the heparin binding domian of vegf and vegfr-2
DE60319135T DE60319135D1 (de) 2002-12-30 2003-12-29 Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
JP2004563063A JP2006523608A (ja) 2002-12-30 2003-12-29 Ｖｅｇｆ及びｖｅｇｆｒ−２のヘパリン結合ドメインに結合するペプチド
AT03781116T ATE386050T1 (de) 2002-12-30 2003-12-29 Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
EP03781116A EP1578785B1 (en) 2002-12-30 2003-12-29 Peptides that bind to the heparin binding domain of vegf and vegfr-2
AU2003288810A AU2003288810A1 (en) 2002-12-30 2003-12-29 Peptides that bind to the heparin binding domian of vegf and vegfr-2
US10/540,431 US20060089307A1 (en) 2002-12-30 2003-12-29 Peptides that bind to the heparin binding domian of vegf and vegfr-2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20026286A NO20026286D0 (no) 2002-12-30 2002-12-30 Nye peptider

Publications (1)

Publication Number Publication Date
NO20026286D0 true NO20026286D0 (no) 2002-12-30

Family

ID=19914347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026286A NO20026286D0 (no) 2002-12-30 2002-12-30 Nye peptider

Country Status (8)

Country Link
US (1) US20060089307A1 (https=)
EP (1) EP1578785B1 (https=)
JP (1) JP2006523608A (https=)
AT (1) ATE386050T1 (https=)
AU (1) AU2003288810A1 (https=)
DE (1) DE60319135D1 (https=)
NO (1) NO20026286D0 (https=)
WO (1) WO2004058802A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US8623822B2 (en) * 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US20080207502A1 (en) * 2004-10-14 2008-08-28 Sopherion Therapeutics, Inc. Anti-Angiogenic Peptides and Methods of Use Thereof
EP1833512A1 (en) 2005-01-06 2007-09-19 GE Healthcare AS Optical imaging
WO2014034922A1 (ja) * 2012-09-03 2014-03-06 国立大学法人東京大学 血管内皮細胞増殖因子受容体阻害ペプチド
KR101531944B1 (ko) * 2013-12-24 2015-06-29 광주과학기술원 Ｖｅｇｆ에 특이적으로 결합하는 ｖｅｇｆ－ｂｐｂ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5928900A (en) * 1993-09-01 1999-07-27 The Rockefeller University Bacterial exported proteins and acellular vaccines based thereon
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US5948667A (en) * 1996-11-13 1999-09-07 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Xylanase obtained from an anaerobic fungus
WO1999010498A2 (en) * 1997-08-27 1999-03-04 Pioneer Hi-Bred International, Inc. Genes encoding enzymes for lignin biosynthesis and uses thereof
EP1015578A4 (en) * 1997-09-17 2004-12-01 Walker And Eliza Hall Inst Of THERAPEUTIC MOLECULES
CA2320339A1 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO2001052875A1 (en) * 2000-01-18 2001-07-26 Ludwig Institute For Cancer Research Vegf-d/vegf-c/vegf peptidomimetic inhibitor
JP4398620B2 (ja) * 2000-02-03 2010-01-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｃｒ−２抗体およびその使用方法
CA2327208A1 (en) * 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
JP2005504025A (ja) * 2001-07-20 2005-02-10 アイトゲネシシェ テクニシェ ホッヒシュル チューリッヒ（エーテーハーツェット） スルフォネート化またはスルフェート化アミノ酸から誘導された生物学的薬剤の使用法と組成物
ES2398393T3 (es) * 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia

Also Published As

Publication number Publication date
ATE386050T1 (de) 2008-03-15
JP2006523608A (ja) 2006-10-19
EP1578785B1 (en) 2008-02-13
AU2003288810A1 (en) 2004-07-22
US20060089307A1 (en) 2006-04-27
EP1578785A1 (en) 2005-09-28
DE60319135D1 (de) 2008-03-27
WO2004058802A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
UA109633C2 (uk) Антитіло людини проти тканинного фактора
DE60028970D1 (de) An her2 bindende peptidverbindungen
ATE394121T1 (de) Verwendung von antikörpern gegen das muc18- antigen
ATE364618T1 (de) Antikörper gegen das muc18-antigen
PT1187918E (pt) Antagonistas de tek
CY1110661T1 (el) Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως
EP1767544A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EP2447280A3 (en) VEGF analogs and methods of use
EA201100694A1 (ru) Антитело к cd38 человека и его применение
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
NO20026286D0 (no) Nye peptider
EA200601217A1 (ru) Новые конденсированные пирролокарбазолы
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
WO2004058803A3 (en) Peptides that bind of the vegfr-2
DE60135158D1 (de) Antagonisten des ige-rezeptors
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
ATE480552T1 (de) Stq-peptide
DE60312684D1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
ATE509957T1 (de) An die a2-domäne bindende, humane inhibitorische anti-faktor-viii-antikörper
WO2023166318A3 (en) Therapeutic antibodies
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
ATE324905T1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall